Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

(2011) Anna Brózik et al.   Expert Opinion on Drug Metabolism & Toxicology

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients

(2011) Bing Long et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

(2011) L F Peterson et al.   LEUKEMIA

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

(2011) V Grossmann et al.   LEUKEMIA

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

(2010) Kevin R. Kelly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity

(2010) J R Engler et al.   LEUKEMIA

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

(2010) F J Giles et al.   LEUKEMIA

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study

(2010) Francis J Giles et al.   Expert Review of Hematology

Current role of stem cell transplantation in chronic myeloid leukaemia

(2009) Alois Gratwohl et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

(2009) D K Hiwase et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

New Directions in the Treatment of Imatinib Failure and/or Resistance

(2009) Francis J. Giles   SEMINARS IN HEMATOLOGY

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

(2008) M. Hazarika et al.   CLINICAL CANCER RESEARCH

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

(2008) Thomas O'Hare et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

(2008) J Cortes et al.   LEUKEMIA

Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia

(2008) Francis J. Giles et al.   SEMINARS IN ONCOLOGY